AssistMe Patent Portfolio Analysis

Money arrives five years after the filings

AssistMe closed a $7.5M round backed by Conle Family Office, Next Big Thing and Sum Ventures. The company was founded in Germany in 2017 and describes itself as building smart assistance solutions to support care. That description is broad enough to cover almost anything. The patent file is not broad. It is specific, dated, and it starts four years before this pulse on the chart.

Rounds are easy to read backwards. The interesting question is what was already true when the cheque cleared. In this case: three granted families, enforceable now, and four more published and pending, the first of which could grant at any time. None of that was built with this money. All of it was built before it.

Three solid ticks, four thin ones

Seven families, filed in Germany, at the EPO and under the PCT. Three have granted. Four remain published applications. The solid marks are the ones that carry rights today; the thin ones are positions still being argued. For a company this size, a three-of-seven grant rate across a portfolio begun in 2021 is a normal, unglamorous record of prosecution actually being done.

Nine inventors are named across the set. Julio Brandl appears on three, Jonas Kathan on three, Lemke Diego Carucci on two. That is a small, repeating core rather than a rotating cast, which usually means the invention came from a fixed engineering team working one problem for years instead of from scattered opportunistic filings.

Three families are granted, which makes them enforceable today.

The burst came first, then quiet

Four families first filed in 2021. One in 2023. Two in 2024. The shape is a front-loaded burst followed by maintenance. Whatever thesis this company had about sensing inside an absorbent article, it committed to it early and in one go, then returned only twice to extend it. The last public filing is dated 19 September 2024.

That date sits twenty-three months before the round. Everything filed since then is still inside the eighteen-month publication window, which is the shaded area on the chart. So the visible portfolio is not the current portfolio. It is the portfolio as of a year and a half ago, and the raise arrives on the far side of a blind spot that only time can open.

Half the claims are not software

The claims cluster in two places. A61F, which covers implants and eye treatment and, more relevantly here, absorbent articles. And G16H, healthcare informatics. The recent titles make the pairing legible: a circuit carrier for a clip that mounts on an absorbent article, a method of joining an absorbent article to a continuous strip, and a system for detecting an incontinence event.

A company that calls itself a digital pioneer has put real weight into physical joining methods and printed circuit carriers. That is the detail worth holding onto. The informatics claims describe what happens after the event is detected. The A61F claims describe the thing that detects it, and how it is manufactured and attached. One of those is much harder to design around.

Philips has nine hundred, they have seven

The same CPC groups drew Philips with 943 families over five years, Samsung with 644, Procter & Gamble with 445, Zhejiang University with 419, Biosense Webster Israel with 388 and Medtronic with 330. On the same scale AssistMe is a dot. Procter & Gamble's presence tells you the absorbent article side of this space is contested by people who have been contesting it for decades.

In a crowded class, count stops meaning anything and scope starts meaning everything. Seven narrowly drafted families aimed at one mechanism can matter more than four hundred spread across a category. One external citation has appeared so far, from Tuli Raja. That is a thin signal, and a young one, but it is the first evidence of someone else's examiner finding this work.

Count stops meaning anything in a crowded class, and scope starts meaning everything.

The hiring tells you the phase

Seventy-one open roles. Twenty-two in go-to-market, fourteen other, twelve in software and AI, eleven in bio and clinical, eight in operations and finance, four in hardware. Customer success, freelance sales in France, working-student support. This is not a research build-out. The invention happened in 2021 and the company is now hiring people to sell what came out of it.

Which puts the filings in an unusual position. They are not a defensive afterthought behind a product. They are the durable part of what the go-to-market team is taking to market: a granted mechanism for detecting an incontinence event, in a class where Procter & Gamble and Philips already stand, held by nine named inventors in Germany. That is the asset. The round is the distribution budget for it.